ArticleFrontiers in immunology2026
Integrated metabolomic and transcriptomic profiling reveals lipid dysregulation and potential biomarkers in interstitial lung disease.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interstitial lung disease (ILD) comprises diverse chronic inflammatory and fibrotic disorders with poorly understood mechanisms and limited diagnostic biomarkers. Growing evidence implicates lipid metabolic reprogramming in ILD pathogenesis, yet integrated metabolomic-transcriptomic analyses remain scarce. We performed combined metabolomic and transcriptomic analysis using publicly available datasets. Plasma metabolite profiles of ILD and lobar pneumonia (LOB) patients were analyzed by NMR-based metabolomics. Multivariate analyses (PCA, PLS-DA, OPLS-DA) identified discriminatory metabolites. KEGG enrichment revealed associated pathways. Transcriptomic data from lung tissue were analyzed for differentially expressed genes, identifying 345 differentially expressed genes (|log2FC| > 0.585, adjusted p < 0.05), integrated with metabolomic data to identify shared pathways. ROC curves evaluated diagnostic performance of key metabolites. To validate the bioinformatic findings, we established a bleomycin (BLM)-induced ILD mouse model with or without high-cholesterol diet (HCD) intervention. RT-qPCR, Western blotting, H&E staining, and Masson's trichrome staining were performed to assess gene expression and histopathological changes in lung tissue. Metabolomic profiling showed clear separation between ILD and LOB samples, driven by alterations in triglyceride-rich lipoproteins, phospholipids, and cholesterol fractions. Seven metabolites were significantly increased in ILD (p < 0.05). Integrated multi-omics identified "lipid and atherosclerosis" as a key shared pathway, encompassing six differential genes (CD36, NFKBIA, PIK3R1, SELP, CCL2, VCAM1) and one differential metabolite (Cholesterol [HDL4]). ROC analysis showed a combined metabolite model achieved AUC of 0.810. Experimental validation confirmed SELP, CCL2, and VCAM1 were upregulated while NFKBIA was downregulated in BLM-treated mice. HCD further aggravated BLM-induced pulmonary fibrosis and markedly elevated the expression of inflammatory cytokines (TNF-α, IL-6, IL-1β) as well as key pathway proteins (SELP, CCL2, VCAM1). This integrated multi-omics analysis reveals a strong link between lipid dysregulation and ILD pathogenesis. Cholesterol fractions, triglycerides, and phospholipids may serve as potential non-invasive biomarkers for ILD, while the lipid and atherosclerosis pathway represents a promising target for therapeutic intervention. Animal experiments further validated that HCD exacerbates ILD via the lipid and atherosclerosis pathway, reinforcing the clinical relevance of cholesterol dysregulation in ILD progression. Our findings provide new insights into the metabolic mechanisms of ILD and establish a foundation for future diagnostic and therapeutic development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.